After a venomous snake bite time is of the essence. We enable immediate bite treatment that delays the neurotoxic and tissue damaging effects of the venom, allowing time to seek help.

Our novel gene editing removes the immunogenicity of human Pluripotent Stem Cells upon implantation into human organs. We have chosen Type 1 Diabetes as the initial indication to demonstrate the potential of our platform.

UArizona researchers have created an AI powered data-driven tool to forecast a personalized due date window for expectant mothers utilizing data from commonly worn personal devices like smart rings at various periods in gestation.

Senfina offers in vivo whole life drug discovery services for aging and age-related diseases based on a multi-feature high-throughput imaging platform using C. elegans as a model organism.

Safe Lactobacillus-based synthetic biologic as a colonization resistance agent of, and oral vaccine for, Clostridioides difficile infection (CDI).

Our data-driven platform integrates high-throughput analytics and AI for next-generation drug discovery. We leverage novel insights into the foundational biologic pathways of neurodegenerative diseases to discover, evaluate, and develop disease-modifying therapeutics for Alzheimer’s disease, frontotemporal dementia (FTD) , amyotrophic lateral sclerosis (ALS), and other degenerative diseases of the nervous system.

The SeVA platform is a composite AI device that can be effectively deployed in hospital, nursing homes and home settings. It has the capability to track a patient’s mental and physical state and signal early signs of risks such as delirium, falls or impending illness. It provides emotional support to the patient and their family by indulging in a natural conversation and facilitating their needs. When fully deployed, the product can serve as a platform which allays worry for people and their caregivers and will reduce healthcare costs by identifying the early signs of severe illness.

Many cancer drugs suffer from severe adverse effects due to acute high exposure and inadequate distribution to tumors. This technology provides a vehicle for the preferred delivery of existing and approved drugs to tumor environments and local release of the active agent, thereby focusing exposure to tissues in need and reducing unwanted side effects.